Afatinib and Erlotinib in the treatment of squamous-cell lung cancer

Author:

Tagliamento Marco1ORCID,Genova Carlo12ORCID,Rijavec Erika1,Rossi Giovanni1,Biello Federica1,Dal Bello Maria Giovanna1,Alama Angela1,Coco Simona1,Boccardo Simona1,Grossi Francesco3

Affiliation:

1. Lung Cancer Unit, Ospedale Policlinico San Martino , Genoa, Italy

2. Department of Internal Medicine and Medical Specialties (DIMI), University of Genoa , Genoa, Italy

3. Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Medical Oncology , Milan, Italy

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Reference64 articles.

1. Stewart BW , Wild CP. World cancer report 2014. Lyon: International Agency for Research on Cancer/World Health Organization; 2014.

2. Cancer Statistics Review, 1975–2014 - SEER statistics [Internet]. 2018 [cited 2018 Apr 1 ]. Available from: https://seer.cancer.gov/csr/1975_2014/.

3. New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib

4. Comprehensive genomic characterization of squamous cell lung cancers

5. Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3